This recent finding raises the possibility that the correlation between high CD2 expression and favorable prognosis of patients with HR−/HER2+ breast cancer in our study is related to the augmentation of NK cytotoxic activity against cancer cells by CD2. The gene discussed is ERBB2; the disease is cancer.